Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071666 | 0.96 | GAA (0.43) | GAAHPGDTHRBMEN1KMT2A | |
| SCHEMBL7076921 | 0.96 | GAA (0.43) | GAAHPGDTHRBMEN1KMT2A | |
| SCHEMBL7076807 | 0.89 | TERT (0.44) | GAAHPGDTHRBALDH1A1SMYD3 | |
| Hydrochloric Acid SCHEMBL7071254 | 0.88 | ITGB3 (0.40) | GAATHRBSMYD3HDAC3HDAC1 | |
| SCHEMBL7073961 | 0.87 | SMYD3 (0.47) | GAAHPGDTHRBMEN1KMT2A | |
| SCHEMBL7075591 | 0.86 | SMYD3 (0.52) | GAAHPGDTHRBMEN1KMT2A | |
| SCHEMBL7073177 | 0.85 | DGAT1 (0.41) | GAAHPGDTHRBMEN1KMT2A | |
| SCHEMBL7075827 | 0.84 | DRD2 (0.37) | GAAITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL7076205 | 0.84 | SMYD3 (0.40) | GAATHRBMEN1KMT2ASMYD3 | |
| Hydrochloric Acid SCHEMBL7075240 | 0.84 | SMYD3 (0.42) | GAATHRBMEN1KMT2ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | GAA 2157/4885HPGD 4097/4885THRB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.